Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical study of CD19 detection methods post tafasitamab treatment.
Ilieva K, Eberl M, Jaehrling J, Blair D, Patra-Kneuer M, Boxhammer R, Alvarez Arias D, Heitmüller C. Ilieva K, et al. Among authors: boxhammer r. Front Immunol. 2023 Oct 20;14:1274556. doi: 10.3389/fimmu.2023.1274556. eCollection 2023. Front Immunol. 2023. PMID: 37928552 Free PMC article.
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Her JH, Pretscher D, Patra-Kneuer M, Schanzer J, Cho SY, Hwang YK, Hoeres T, Boxhammer R, Heitmueller C, Wilhelm M, Steidl S, Endell J. Her JH, et al. Among authors: boxhammer r. Cancer Immunol Immunother. 2022 Nov;71(11):2829-2836. doi: 10.1007/s00262-022-03165-w. Epub 2022 Mar 29. Cancer Immunol Immunother. 2022. PMID: 35348812 Free PMC article.
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Mayer KA, Budde K, Halloran PF, Doberer K, Rostaing L, Eskandary F, Christamentl A, Wahrmann M, Regele H, Schranz S, Ely S, Firbas C, Schörgenhofer C, Kainz A, Loupy A, Härtle S, Boxhammer R, Jilma B, Böhmig GA. Mayer KA, et al. Among authors: boxhammer r. Trials. 2022 Apr 8;23(1):270. doi: 10.1186/s13063-022-06198-9. Trials. 2022. PMID: 35395951 Free PMC article.
α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
Teiluf K, Seidl C, Blechert B, Gaertner FC, Gilbertz KP, Fernandez V, Bassermann F, Endell J, Boxhammer R, Leclair S, Vallon M, Aichler M, Feuchtinger A, Bruchertseifer F, Morgenstern A, Essler M. Teiluf K, et al. Among authors: boxhammer r. Oncotarget. 2015 Mar 10;6(7):4692-703. doi: 10.18632/oncotarget.2986. Oncotarget. 2015. PMID: 25576914 Free PMC article.
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.
Busch L, Mougiakakos D, Büttner-Herold M, Müller MJ, Volmer DA, Bach C, Fabri M, Bittenbring JT, Neumann F, Boxhammer R, Nolting J, Bisht S, Böttcher M, Jitschin S, Hoffmann MH, Balzer H, Beier F, Gezer D, Dudziak D, Gelse K, Hennig FF, Pallasch CP, Spriewald B, Mackensen A, Bruns H. Busch L, et al. Among authors: boxhammer r. Leukemia. 2018 Nov;32(11):2445-2458. doi: 10.1038/s41375-018-0114-0. Epub 2018 Mar 28. Leukemia. 2018. PMID: 29654274
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, Haindl S, Kasbohm S, Kainz A, Eskandary F, Doberer K, Patel UD, Dudani JS, Regele H, Kozakowski N, Kläger J, Boxhammer R, Amann K, Puchhammer-Stöckl E, Vietzen H, Beck J, Schütz E, Akifova A, Firbas C, Gilbert HN, Osmanodja B, Halleck F, Jilma B, Budde K, Böhmig GA. Mayer KA, et al. Among authors: boxhammer r. N Engl J Med. 2024 May 25. doi: 10.1056/NEJMoa2400763. Online ahead of print. N Engl J Med. 2024. PMID: 38804514